BALAXI PHARMACEUTICALS liquidity ratios

·UnclassifiedChart ›

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

3.30×	—	—	—	—	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
4.05×	4.05×	4.45×	3.88×	3.64×
2.70×	2.70×	3.01×	2.36×	1.67×
14.6	14.6	39.4	62.3	28.2
189	189	188	156	140

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

BALAXI₹19.71

BALAXI PHARMACEUTICALS LIMITED

· Unclassified

₹ CrorePeersPAR STEELCITY LATTEYS CROWN HECPROJECT HINDCON AIROLAM GROBTEAMcap ₹109 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Altman Z-Score (Other Equity as RE)	—	—	—	—	3.30
Current Ratio	3.64	3.88	4.45	4.05	4.05
Quick Ratio	1.67	2.36	3.01	2.70	2.70
Cash, Equiv & ST Investments	28.2	62.3	39.4	14.6	14.6
Working Capital	140.4	156.0	188.2	189.3	189.3

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.